Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | BPTF | Q12830 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1594749 | 0.86 | ALDH1A1 (0.32) | ALDH1A1GAABPTFMEN1KMT2A | |
| SCHEMBL25245007 | 0.81 | — | — | |
| SCHEMBL189533 | 0.80 | POLB (0.48) | ALDH1A1KDM4EHPGDGAABPTF | |
| SCHEMBL25909650 | 0.79 | ALDH1A1 (0.57) | ALDH1A1BPTFTSHRKMT2AP2RX7 | |
| SCHEMBL1074062 | 0.79 | ALDH1A1 (0.57) | ALDH1A1BPTFTSHRKMT2AP2RX7 | |
| SCHEMBL7412340 | 0.78 | ALDH1A1 (0.39) | ALDH1A1KDM4EHPGDGAABPTF | |
| SCHEMBL11577622 | 0.76 | GAA (0.60) | ALDH1A1GAATSHRPOLBMEN1 | |
| SCHEMBL7594583 | 0.75 | ALDH1A1 (0.37) | ALDH1A1KDM4EHPGDGAABPTF | |
| SCHEMBL418818 | 0.74 | KDM4E (0.35) | ALDH1A1KDM4EHPGDGAABPTF | |
| SCHEMBL7082780 | 0.74 | ALDH1A1 (0.34) | ALDH1A1KDM4EHPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010115869-A1 | PROPOFOL PHOSPHONYL DERIVATIVES, SYNTHESIS, AND USE IN LONG ACTING FORMULATIONS | SEPS PHARMA N.V. (BE) | 2010-10-14 | — | — | WO | claimed |
| US-8962639-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8779183-B2 | Acid generating agent for chemically amplified resist compositions | KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) | 2014-07-15 | — | — | US | disclosed |
| EP-1719762-B1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | EISAI R&D MAN CO LTD (JP) | 2012-06-27 | — | — | EP | disclosed |
| WO-2010138828-A2 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305109-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010115869-A1 | PROPOFOL PHOSPHONYL DERIVATIVES, SYNTHESIS, AND USE IN LONG ACTING FORMULATIONS | SEPS PHARMA N.V. (BE) | 2010-10-14 | — | — | WO | disclosed |
| US-20090234155-A1 | Acid generating agent for chemically amplified resist compositions | KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) | 2009-09-17 | — | — | US | disclosed |
| US-7531532-B2 | Hepatocyte growth factor receptor inhibitors; Antitumor agents, anticarcinogenic agents, angiogenesis inhibitors; pyrimidine derivatives like Pyrrolidine-1-carboxylic acid [6-(2-fluoro-4-{3-[2-(4-fluorophenyl)acetyl]thioureido}phenoxy)pyrimidin-4-yl]amide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| EP-1719763-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (2) | Eisai Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1719762-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | Eisai Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | EISAI CO., LTD. (JP) | 2005-12-15 | — | — | US | disclosed |
| EP-1111466-A1 | The chemical amplified resist composition containing norbornane type low molecular additive | Korea Kumho Petrochemical Co. Ltd. (KR) | 2001-06-27 | — | — | EP | disclosed |
| WO-1993000359-A1 | MODIFIED PEPTIDES TRANSPORTABLE INTO THE CENTRAL NERVOUS SYSTEM | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | HGF, MET, FLT1 | ALDH1A1 557/4885KDM4E 4069/4885HPGD 472/4885 |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | HGF, MET, HDGF | ALDH1A1 930/4885KDM4E 4122/4885HPGD 394/4885 |
| US-20090234155-A1 | Acid generating agent for chemically amplified resist compositions | POLM, CBR1, PFAS | ALDH1A1 346/4885KDM4E 3728/4885HPGD 1917/4885 |
| US-20100305109-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNJ2 | ALDH1A1 1031/4885KDM4E 680/4885HPGD 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.